Research Paper

The Effect of Omega-3 Supplementation on Serum Levels of Antioxidant Status in Patients With Bipolar Disease: A Randomized Double-blind Controlled Clinical Trial

Dina Gholipour1,2, Mansour Shahraki2,3, Mohsen Saravani4,5, Abolfazl Payandeh6, Hadi Eslahi1,2*

1. Student Research Committee, Zahedan University of Medical Sciences, Zahedan, Iran.
2. Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
3. Children and Adolescents Health Research Center; Research Institute of Cellular and Molecular Science in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, Iran.
4. Cellular and Molecular Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran.
5. Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
6. Community Nursing Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.

* Corresponding Author:
Hadi Eslahi
Address: Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Tel: +98 (918) 8410265
E-mail: hadi_eslahi2015@yahoo.com

ABSTRACT

Introduction: Antioxidants prevent the progression of neuropsychiatric disorders, such as bipolar disorder (BD). Omega-3 fatty acid supplementation helps prevent lipid peroxidation and improve antioxidant status. This study aims to investigate the effect of omega-3 supplementation on serum levels of antioxidant status in patients with BD.

Methods: In this study, 28 patients with BD received an omega-3 fatty acid supplement (2 g/daily) while the other 28 patients received edible paraffin oil (2 g/daily) for 60 days. The activities of superoxide dismutase (SOD), catalase (CAT), and total antioxidant capacity (TAC) were evaluated in pre-intervention and post-intervention.

Results: The results showed that omega-3 supplementation increased the activities of SOD (12.94±3.84 U/mL vs 17.72±3.59 U/mL) and CAT (5.08±1.61 nmol/min/mL vs 6.43±1.33 nmol/min/mL) in post-intervention compared to pre-intervention (P=0.001). The results also showed that omega-3 supplementation increased the activities of SOD (17.72±3.59 U/mL vs 13.79±3.12 U/mL) and CAT (6.43±1.33 nmol/min/mL vs 4.89±1.45 nmol/min/mL) compared to the control group in post-intervention (P=0.001). Omega-3 supplementation did not have significant effects on the serum concentration of TAC compared to pre-intervention (P=0.373) and control group (P=0.604).

Conclusion: Omega-3 supplementation increased the activities of SOD and CAT and may decrease the progression of disease via increasing antioxidant status.

Keywords: Antioxidant capacity, Bipolar disease, Catalase, Omega-3
Highlights

- Bipolar disorder (BD) is characterized by mood fluctuations, such as mania, hypomania, mixed episodes, and depression.
- Oxidative stress is an effective factor in the progression of bipolar disorder.
- Bipolar disorder imbalances oxidant-antioxidant balance, and omega-3 supplement may improve the balance in patients with BD.

Plain Language Summary

Bipolar disorder (BD) is a chronic disorder and is associated with fluctuations in mood and energy. Oxidative stress is an important factor in the development of BD. Several studies have reported changes in antioxidant enzymes among patients with BD. Several enzymes and factors play a role in preventing the progression of this disorder, such as superoxide dismutase (SOD), catalase (CAT), and total antioxidant capacity (TAC). Some studies have concluded that omega-3 fatty acids have antioxidant properties. But some other studies have not observed such an effect for omega-3. Therefore, according to these contradictions, the present study was conducted by examining the effect of omega-3 on the serum level of antioxidant status on 56 patients in two groups of cases and controls. 28 patients with BD received omega-3 fatty acid supplementation (2 g/day), while another 28 patients received oral paraffin oil (2 g/day) for 60 days, and the activity of SOD, CAT, and TAC were evaluated before and after the intervention. The results showed that omega-3 supplementation increases the activity of SOD and CAT and may reduce the progression of the disease by improving the antioxidant status.

1. Introduction

Bipolar disorder (BD) is a chronic disorder affecting 1% of people worldwide and causes disability in young people (Viesta et al., 2018). This disorder is associated with co-morbid systemic illnesses, morbidity, faulted function, and a high risk of suicide and mortality (Patel et al., 2018). The disease is characterized by mood fluctuations, such as mania, hypomania, mixed episodes, and depression (Lokeshu et al., 2020). Several factors are involved in the etiology of the disorders. Oxidative stress is an effective factor in the progression of BD (Anderson & Maes, 2015). Mood stabilizers have antioxidant properties protecting brain cells from dysfunction and apoptosis (Jiménez-Fernández et al., 2021). Oxidative stress is significantly higher in patients with BD compared to the general population (Anderson & Maes, 2015). Oxidative stress diminishes neuroplasticity and neurogenesis while increasing apoptosis and neurodegeneration in patients with BD and depression (Fornito et al., 2007; Maes et al., 2009). Several studies have reported changes in antioxidant enzymes among patients with BD (Cudney et al., 2014; de Sousa et al., 2014; Mansur et al., 2016). Studies have reported that antioxidant supplementation reduces symptom burden in patients with BD (Berk et al., 2013; Sommer et al., 2014). Several enzymes and factors are involved in the prevention of progressions of the disorder, such as superoxide dismutase (SOD), catalase (CAT), and total antioxidant capacity (TAC) (Jahangard et al., 2019; Rahsepar & Mohammadpour, 2021; Siwek et al., 2013). Hence, supplementation of antioxidant structures helps to improve antioxidant balance and may be beneficial in patients with BD.

Omega-3 fatty acids play a vital role in the body and participate in regulating the active transport of amino acids by the cell membrane, the function of sodium channels as well as starting the response of rhodopsin to visual stimuli (Djuricic & Calder, 2021). Omega-3 fatty acids change the balance of reductive and oxidative species and have roles in glucose and lipid metabolism (Amos et al., 2019; Sarris et al., 2011). Lagarde and Calzada reported the antioxidant properties of polyunsaturated fatty acids (Guillot et al., 2009). Omega-3 fatty acids have been suggested as antioxidants in the brain (Yavin et al., 2002). A review article concluded that omega-3 fatty acids have antioxidant properties (Giordano & Visioli, 2014). Parellada et al. did not report significant effects of omega-3 on antioxidant status (Parellada et al., 2017). Avramovic and others reported positive effects of omega-3 fatty acids in increasing SOD and decreasing lipid peroxidation (Avramovic et al., 2012). Barbora

Katrenčíková et al investigated markers of oxidative stress and antioxidant enzymes in people with depressive disorder and reported that omega-3 may diminish oxidative stress (Katrenčíková et al., 2021).

In sum, BD imbalances oxidant-antioxidant balance, and omega-3 supplementation may improve the balance in patients with BD. In addition, examining the intake and metabolism of omega-3 supplementation has provided clues that may be crucial for treating BD (Saunders et al., 2016). Thus, omega-3 supplementation is beneficial in patients with BD compared to the population. This study was conducted to evaluate the effects of omega-3 supplementation on serum levels of antioxidant status in patients with BD by examining the serum concentrations of CAT, SOD and TAC.

2. Materials and Methods

Participants

This randomized clinical trial study was conducted on 56 men and women with BD referred to Baharan Hospital (Zahedan City-Iran) in 2021. The inclusion criteria included male and female patients aged 18-65 years without a change in the medication schedule, without a history of taking omega-3 supplementation and having literacy and consent to participate in the study. The exclusion criteria included patients with schizophrenia, cardiac disorders, and mental retardation, and programming for surgery and patients who changed drug dosages disagreed to participate in the study and were allergic to drugs. Informed consent was received at the beginning of the study.

Randomization and allocation

A total of 56 patients were randomly divided into two homogenous groups. The patients were allocated into groups using stratified permuted block randomization. The patients were classified based on age and gender. Quadruple blocks (both groups and two replications for each group) were randomly selected from permutes and assigned to groups with the help of R software, version 4.0.2. Both groups were matched in terms of sex and age based on frequency matching and with the help of stratified permuted block randomization. Double blinding was conducted and people distributing supplements and intervening and technicians registering outcomes had no information for the study. Groups included omega-3 (14 men and 14 women) and placebo (14 men and 14 women). The patients in the omega-3 and the placebo groups daily received 2 g of omega-3 in gel form and 2 g of paraffin, respectively. Omega-3 and paraffin were prepared by Barij-essence Company (Kashan City-Iran). This study lasted for two months. The patients and lab staff responsible for lab analysis had no information about supplements and interventions. We also collected the data for demographic characteristics. We also collected the data for demographic characteristics. The sample size was calculated based on previous studies (Safari, 2010) and based on the Equation 1.

\[ n_1 = n_2 = \frac{(\frac{(\alpha + \beta)^2}{\sigma^2}(1 + \frac{1}{k})}{(\epsilon - \delta)^2} \]

Where, \( n_1 \) and \( n_2 \) show the number of samples in omega-3 and placebo groups, respectively. Also, \( \kappa, \alpha, 1-\beta, \sigma^2, \epsilon, \) and \( \delta \) show the number of samples in omega-3 to placebo, probability of type 1 error, statistical power, the mixed variance of groups, real difference, and clinical effective limit, respectively.

Assessment of antioxidant status

At the beginning and end of the study, blood samples (5 mL) were collected to investigate the serum concentrations of SOD, CAT, and TAC at 8 AM, and transferred into microtubes. The blood samples were centrifuged at 3500 rpm and serum was stored at -70ºC. SOD and CAT activities and TAC were measured by commercial kits (Kiazist, Iran) as suggested by the manufacturer. To investigate SOD activity, tetrazolium salt was used to detect superoxide radicals generated by xanthine oxidase and hypoxanthine. To investigate CAT, the enzymatic conversion of methanol to formaldehyde was used in the presence of an optimal concentration of hydrogen peroxide (H₂O₂).

Data analysis

Data related to demographic information were reported as frequency. The data for the antioxidant status were investigated for normality. Since the data were normal, we analyzed them by the parametric procedure of t-test. The data are reported as Mean±SD.

3. Results

Demographic data

Table 1 presents the results of the demographic characteristics. The results showed no significant difference between groups in terms of age (P=0.415), height (P=0.562), weight (P=0.875), and body mass index (BMI) (P=0.751). The groups were similar in gender. The mean age was 42.05±8.97 years in the placebo
## Table 1. Demographic data

<table>
<thead>
<tr>
<th>Demographic</th>
<th>Control</th>
<th>Case</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>42.05±8.97</td>
<td>39.97±12.32</td>
<td>0.415</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>171.20±14.56</td>
<td>174.20±5.08</td>
<td>0.562</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>68.05±2.43</td>
<td>65.14±6.23</td>
<td>0.875</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.46±5.30</td>
<td>21.72±3.60</td>
<td>0.751</td>
</tr>
<tr>
<td>Marital states</td>
<td>6(21.42)</td>
<td>10(35.70)</td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>22(78.58)</td>
<td>18(64.30)</td>
<td></td>
</tr>
<tr>
<td>Education</td>
<td>&lt;Diploma</td>
<td>20(71.42)</td>
<td>18(64.30)</td>
</tr>
<tr>
<td>Diploma</td>
<td>8(28.58)</td>
<td>10(35.70)</td>
<td></td>
</tr>
</tbody>
</table>

## Table 2. The effect of omega-3 supplementation on the activity of SOD (U/mL) in patients with BD

<table>
<thead>
<tr>
<th>Groups</th>
<th>Pre-intervention</th>
<th>Post-intervention</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omega-3</td>
<td>12.94±3.84</td>
<td>17.72±3.59</td>
<td>0.000</td>
</tr>
<tr>
<td>Control</td>
<td>14.18±2.80</td>
<td>13.79±3.12</td>
<td>0.589</td>
</tr>
<tr>
<td>P**</td>
<td>0.188</td>
<td>0.000</td>
<td>-</td>
</tr>
</tbody>
</table>

*Independent t-test, **Dependent t-test.

## Table 3. The effect of omega-3 supplementation on the activity of CAT (nmol/min/mL) in patients with BD

<table>
<thead>
<tr>
<th>Groups</th>
<th>Pre-intervention</th>
<th>Post-intervention</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omega-3</td>
<td>5.08±1.61</td>
<td>6.43±1.33</td>
<td>0.000</td>
</tr>
<tr>
<td>Control</td>
<td>5.07±1.82</td>
<td>4.89±1.45</td>
<td>0.622</td>
</tr>
<tr>
<td>P**</td>
<td>0.986</td>
<td>0.001</td>
<td>-</td>
</tr>
</tbody>
</table>

*Independent t-test, **Dependent t-test.

## Table 4. The effect of omega-3 supplementation on TAC (nmol of trolox equivalent/mL) in patients with BD

<table>
<thead>
<tr>
<th>Groups</th>
<th>Pre-intervention</th>
<th>Post-intervention</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omega-3</td>
<td>366.78±93.68</td>
<td>351.28±62.10</td>
<td>0.373</td>
</tr>
<tr>
<td>Control</td>
<td>342.21±54.88</td>
<td>359.03±56.86</td>
<td>0.309</td>
</tr>
<tr>
<td>P**</td>
<td>0.248</td>
<td>0.604</td>
<td>-</td>
</tr>
</tbody>
</table>

*Independent t-test, **Dependent t-test.
group and 39.97±12.32 years in the case group. The mean of height was 174.20±14.56 cm and 179.20±5.08 cm in the placebo and omega-3 groups, respectively. The mean of weight was 68.05±2.43 kg and 65.14±6.23 kg in the case and control groups, respectively. In both groups, most patients were married and had educational levels lower than a diploma. No significant differences were observed between groups (P=0.05) affecting antioxidant results.

4. Discussion

This study was conducted to investigate the effects of omega-3 supplementation on the activities of SOD and CAT and TAC. The results showed that omega-3 supplementation significantly increased activities of SOD (P=0.000) and CAT (P=0.000) in post-intervention compared to pre-intervention. It also increased activities of SOD (P=0.000) and CAT (P=0.000) compared to the control group in post-intervention. Omega-3 supplementation significantly increased activities of SOD (21%) and CAT (27%) in post-intervention compared to pre-intervention. Omega-3 supplementation did not have significant effects on TAC in post-intervention compared to pre-intervention (P=0.373) and compared to the control group (P=0.604).

5. Conclusion

In sum, omega-3 supplementation increased the activities of SOD and CAT and omega-3 supplement compensates antioxidant faults and improves antioxidant status in terms of activities of SOD and CAT. However, the results showed that omega-3 supplementation had no significant effect on TAC. The results regarding the effects of the omega-3 supplement on TAC contradict those reported by others (Heshmati et al., 2019; Sepidarkish et al., 2020; Taghizadeh et al., 2017). It was expected that omega-3 supplementation can increase TAC but no such result was observed. Although omega-3 supplementation improved the activities of SOD and TAC, it did not show significant effects on TAC, which can be attributed to different efficiency and mechanisms of omega-3 on various antioxidant parameters.
Ethical Considerations

Compliance with ethical guidelines

This study was approved by the Ethical Committee of Zahedan University of Medical Sciences (Code: IR.ZAMUS.REC.1400,381). The study was registered by the Iranian Registry of Clinical Trials (IRCT) (Code: IRCT20211220053469N2).

Funding

This research was supported by the research project (No.: 10504), funded by the Student Research Committee of Zahedan University of Medical Sciences.

Authors’ contributions

Conceptualization and supervision: Hadi Eslahi and Dina Gholipour; Methodology: Mansour Shahraki and Mohsen Saravani; Data collection: Hadi Eslahi; Investigation: Hadi Eslahi and Dina Gholipour; Data analysis: Abolfazl Payandeh; The original draft preparation: Hadi Eslahi and Dina Gholipour; Review & editing: All authors.

Conflict of interest

The authors declared no conflict of interest.

Acknowledgments

The authors appreciate Zahedan University of Medical Sciences for approving the study and also all people who participated in this study.

References


